SCG CELL-Home

Target Pathogen to Prevent and

Cure Cancer

SCG Cell Therapy is a clinical-stage biotechnology company focusing on the development of novel immunotherapies for patients with pathogenic infections and associated cancers.

LEARN MORE

Target Pathogen to Prevent and

Cure Cancer

SCG Cell Therapy Ptd Ltd is a clinical-stage biotechnology company focusing on the development of novel immunotherapies for patients with pathogenic infections and associated cancers.

LEARN MORE

넳 넲

ABOUT US

SCG Cell Therapy, our name reflects who we are as an international team located in Singapore, China and Germany. We combine the regional strengths of S-C-G to translate state-of-the art scientific and innovative technologies to novel immunotherapies.

Our strategy is to harness patient’s immune system by redirecting cellular responses towards antigens expressed on solid tumors using adoptive cellular transfer. We have developed a proprietary T-cell receptor (TCR) screening platform enable us to identify high affinity and high avidity natural TCRs that can recognize peptide-major histocompatibility complex (pMHC) ligand and trigger cell-mediated immune response. We have developed a leading TCR T cell therapy pipeline for pathogen-associated cancers.

● SCG is developing an industry-leading immunotherapy pipeline for the treatment of chronic infections and pathogen-related solid tumors, combining multiple platforms and proprietary insights to provide solutions for patients who need better prevention and treatment of cancer.

OUR PIPELINE

MORE +

Latest News

MORE +

Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular

넶703 2023-11-14

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

넶839 2023-07-19

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

넶781 2023-07-12

ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy

SINGAPORE, June 5, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell (TCR-T) Therapy – SCG101 – at the International Society for Cell & Gene Therapy (ISCT) conference in Paris, France.

넶1347 2023-06-05

COOPERATIVE PARTNER

E-mail:

info@scgcell.com

Email Contact

Shanghai,China

100 Banxia Road, Building 21 Pudong District

Shanghai, China 201318

Other Locations

Munich,Germany

Am Klopferspitz 19

House 5, 1 Floor

82152 Planegg Germany

Singapore

138 Depot Road #04-02 Singapore 109683

Head Office

Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy